Concordance of PD-L1 status in primary gastroesophageal adenocarcinoma and matched peritoneal metastases: a single institution study

Autor: V. Massa, F. Signorini, F. Salani, M.E. Filice, G. Grelli, P. Lippolis, P. Faviana, V. Genovesi, S. Santi, C. Vivaldi, S. Cesario, A. Bertolucci, C. Cremolini, V. Nardini, G. Masi, C. Ugolini, L. Fornaro

Publikováno v: ESMO Gastrointestinal Oncology, Vol 5, Iss , Pp 100089- (2024)

Background: Programmed death-ligand 1 (PD-L1) expression serves as a predictive biomarker for response to immune checkpoint inhibitors (ICIs) in metastatic gastroesophageal adenocarcinoma (mGEA). The peritoneum is one of the most common metastatic si

Externí odkaz: https://doaj.org/article/363c31ba4cd042449b7e5199c56f6c1e

Comparative efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal or gastric cancer: a global retrospective study

Autor: G. Mazzoli, F. Nichetti, K. Shitara, R. Cohen, S. Lonardi, C. Cremolini, M.E. Elez, J. Chao, M. Fakih, S.J. Klempner, P. Jayachandran, S. Maron, D. Cowzer, L. Fornaro, L. Salvatore, V. Zhu, Y. Aoki, R. Cerantola, F. Bergamo, M. Salati, M. Ambrosini, G. Sabella, G. Randon, M.J. Overman, T. André, F. Pietrantonio

Publikováno v: ESMO Gastrointestinal Oncology, Vol 3, Iss , Pp 100037- (2024)

Background: Programmed cell death protein 1 (PD-1) blockade improved the survival of patients with mismatch repair deficient (dMMR) and/or microsatellite instability-high (MSI-H) tumors, leading to tumor-agnostic approval of pembrolizumab in this pop

Externí odkaz: https://doaj.org/article/0c37cc0360804ca5b240475f9112cdce

Reply to S. Zhang, L. Fornaro et al, and H.J. Lee et al.

Autor: Qin S; Shukui Qin, People's Liberation Army Cancer Center, Bayi Hospital of People's Liberation Army, Nanjing, People's Republic of China; Jin Li, Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China., Li J; Shukui Qin, People's Liberation Army Cancer Center, Bayi Hospital of People's Liberation Army, Nanjing, People's Republic of China; Jin Li, Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2016 Nov 01; Vol. 34 (31), pp. 3823-3824.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.